Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
| ▸ | DRD3 | P35462 | 1/20 | 0.75 |
| ▸ | UBE2M | P61081 | 1/20 | 0.52 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997907 | 0.90 | DRD2 (0.76) | DRD2DRD3UBE2MDCUN1D1ACHE | |
| SCHEMBL1022646 | 0.89 | DRD2 (0.72) | DRD2DRD3UBE2MDCUN1D1ACHE | |
| SCHEMBL31635706 | 0.86 | DRD2 (0.78) | DRD2DRD3UBE2MDCUN1D1ACHE | |
| SCHEMBL1020863 | 0.86 | DRD2 (0.78) | DRD2DRD3UBE2MDCUN1D1ACHE | |
| Jnj-37822681 SCHEMBL1022639 | 0.86 | DRD3 (1.00) | DRD2DRD3ACHESIGMAR1ALDH1A1 | |
| Jnj-37822681 SCHEMBL30349143 | 0.86 | DRD3 (1.00) | DRD2DRD3ACHESIGMAR1ALDH1A1 | |
| Jnj-37822681 SCHEMBL29634868 | 0.86 | DRD3 (1.00) | DRD2DRD3ACHESIGMAR1ALDH1A1 | |
| SCHEMBL1022610 | 0.84 | DRD2 (0.82) | DRD2DRD3UBE2MDCUN1D1ACHE | |
| SCHEMBL5024863 | 0.84 | DRD2 (0.54) | DRD2DRD3UBE2MDCUN1D1ACHE | |
| SCHEMBL4995640 | 0.83 | DRD2 (0.82) | DRD2DRD3UBE2MDCUN1D1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751860-B2 | Piperidin-4YL-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-05 | — | — | US | disclosed |
| US-20170022181-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DE BRUYN MARCEL FRANS LEOPOLD (BE) | 2017-01-26 | — | — | US | disclosed |
| US-9468640-B2 | Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2016-10-18 | — | — | US | disclosed |
| US-20150141432-A1 | PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-21 | — | — | US | disclosed |
| US-8940743-B2 | Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-27 | — | — | US | disclosed |
| CN-101291925-B | Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2013-04-10 | — | — | CN | disclosed |
| EP-1943242-B1 | PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-01-12 | — | — | EP | disclosed |
| CN-101291925-A | Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-22 | — | — | CN | disclosed |
| US-20080227791-A1 | treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects; N-[1-(4-fluorobenzyl)piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022181-A1 | FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2A, GRIN2C | DRD2 1/4885DRD3 14/4885UBE2M 3038/4885 |
| US-20080227791-A1 | treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects; N-[1-(4-fluorobenzyl)piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine | GRIN2C, GRIN2A, GRIN3A | DRD2 20/4885DRD3 42/4885UBE2M 3211/4885 |
| US-20150141432-A1 | PIPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS | DRD2, GRIN2C, GRIN2A | DRD2 1/4885DRD3 10/4885UBE2M 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.